933 reports of this reaction
3.3% of all OBINUTUZUMAB reports
#5 most reported adverse reaction
PYREXIA is the #5 most commonly reported adverse reaction for OBINUTUZUMAB, manufactured by Genentech, Inc.. There are 933 FDA adverse event reports linking OBINUTUZUMAB to PYREXIA. This represents approximately 3.3% of all 28,651 adverse event reports for this drug.
Patients taking OBINUTUZUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among OBINUTUZUMAB users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for OBINUTUZUMAB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 933 FDA reports for OBINUTUZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 3.3% of all adverse event reports for OBINUTUZUMAB, making it a notable side effect.
If you experience pyrexia while taking OBINUTUZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.